natgillin/translations-raw huggingface dataset:
- Pioglitazone Teva 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side. 
- Tablete zdravila Pioglitazon Teva 45 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
Teva UK Ltd Brampton Road, Hampden Park, Eastbourne, 
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Velika Britanija
Pioglitazone Teva 30 mg tablets Each tablet contains 30 mg of pioglitazone (as hydrochloride). 
Pioglitazon Teva 30 mg tablete Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
- Pioglitazone Teva 15 mg tablets are white to off white, round, convex with the number ‘15' on one side and ‘TEVA' on the other side. 
- Tablete zdravila Pioglitazon Teva 15 mg so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5). 
(induktor citokroma P450 2C8) poviša oziroma zniža plazemsko koncentracijo pioglitazona (glejte poglavje 4.5).
If you stop using Pioglitazone Teva, your blood sugar may go up. 
Če ste prenehali jemati zdravilo Pioglitazon Teva, se vam lahko raven krvnega sladkorja zviša, zato se posvetujte z zdravnikom, preden prenehate s tem zdravljenjem.
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea as triple oral therapy in combination with 
s sulfonilsečnino, samo pri bolniki, ki kažejo intolerance na metformin ali pri katerih je metformin kontraindiciran, z nezadostnim nadzorom glikemije kljub najvišjemu toleriranemu odmerku monoterapije s sulfonilsečnino.
Pioglitazone Teva 45 mg tablets Each tablet contains 45 mg of pioglitazone (as hydrochloride). 
Pioglitazon Teva 45 mg tablete Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, convex and debossed with the number ‘45' on one side and ‘TEVA' on the other side. 
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »45« na eni strani in »TEVA« na drugi strani.
The tablets are white to off-white, round, convex and debossed with the number ‘30' on one side and ‘TEVA' on the other side. 
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »30« na eni strani in »TEVA« na drugi strani.
Pioglitazone Teva 15 mg tablets Each tablet contains 15 mg of pioglitazone (as hydrochloride). 
Pioglitazon Teva 15 mg tablete Ena tableta vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Pioglitazone Teva 30 mg tablets Pioglitazone 
Pioglitazone Teva 30 mg tablete pioglitazon
Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. 
koronarnih revaskularizacij in revaskularizacij nog, rezultati kažejo, da ni dolgoročnih kardiovaskularnih skrbi glede uporabe pioglitazona.
Each tablet contains 45 mg pioglitazone (as hydrochloride). 
Ena tableta vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
not known (frequency cannot be estimated from the available data) - increase in liver enzymes - allergic reactions 
- težave s spanjem (nespečnost) neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti)
Pioglitazone Teva 15 mg tablets Pioglitazone 
Pioglitazone Teva 15 mg tablete pioglitazon
Carmellose calcium Hydroxypropylcellulose Magnesium stearate 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi manitol kalcijev karmelozat hidroksipropilceluloza magnezijev stearat
Each tablet contains 30 mg pioglitazone (as hydrochloride). 
Ena tableta vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
The tablets are white to off-white, round, convex and debossed with the number ‘15' on one side and ‘TEVA' on the other side. 
Tablete so bele do umazano bele barve, okrogle, izbočene, z oznako »15« na eni strani in »TEVA« na drugi strani.
Each tablet contains 15 mg pioglitazone (as hydrochloride). 
Ena tableta vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. 
Neželeni učinki, o katerih so poročali večkrat (> 0,5 %) kot pri placebu in več kot enkrat pri bolnikih,
Pioglitazone Teva contains pioglitazone. 
Zdravilo Pioglitazon Teva vsebuje pioglitazon.
Each Pioglitazone Teva 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride). 
Ena 30-miligramska tableta Pioglitazon Teva vsebuje 30 mg pioglitazona (v obliki pioglitazonijevega klorida).
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov) - okužba dihal - motnje vida
common common common common common arthralgia common common common back pain common 
rak sečnega mehurja občasni občasni občasni občasni občasni
Pioglitazone Teva may be used on its own in patients who are unable to take metformin, and where treatment with diet and exercise has failed to control blood sugar or may be added to other therapies (such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood sugar. 
Zdravilo Pioglitazon Teva lahko uporabljamo samo ali skupaj z metforminom in / ali sulfonilsečnino, ki je tudi peroralno antidiabetično zdravilo.
Each Pioglitazone Teva 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride). 
Ena 45-miligramska tableta Pioglitazon Teva vsebuje 45 mg pioglitazona (v obliki pioglitazonijevega klorida).
Each Pioglitazone Teva 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride). 
Ena 15-miligramska tableta Pioglitazon Teva vsebuje 15 mg pioglitazona (v obliki pioglitazonijevega klorida).
Elimination 
Odmerjanje
Gastrointestinal disorders flatulence uncommon common 
Bolezni prebavil flatulenca občasni
Posology 
ZDRAVILA
It is especially important to mention these: 
Posebno pomembno je omeniti naslednje:
• At the request of the European Medicines Agency; 
• Na zahtevo Evropske agencije za zdravila;
Date of first authorisation: 22 August 2016 
Datum prve odobritve: 22 avgust 2016
No deaths were reported. 
O smrtnih primerih niso poročali.
** Based on historical comparison. 
**Na osnovi predhodnih primerjav.
(See sections 4.2 and 4.4.) 
(glejte poglavji 4.2 in 4.4.)
15 to less than 35 
15 do manj kot 35
The clinical relevance of these non-clinical data is unknown. 
Klinični pomen teh nekliničnih podatkov ni znan.
The mechanism of this decrease is unknown. 
Mehanizem za to zmanjšanje ni znan.
Confidence interval. 
Interval zaupanja.
Biosciences, South San Francisco, California, USA) 
Biosciences, South San Francisco, Kalifornija, ZDA)
These could be symptoms of a serious heart problem. 
To so lahko simptomi resnih težav s srcem.
Wait and take the next dose at its regular time. 
Počakajte in vzemite naslednji odmerek ob običajnem času.
It is normally used in combination with other anti-HIV medicines. 
Običajno se predpisuje v kombinaciji z drugimi zdravili proti HIV.
In some patients additional factor VIII was given. 
Nekateri bolniki so prejeli dodaten faktor VIII.
During the second and third trimesters of pregnancy 
Drugo in tretje trimesečje nosečnosti
Paediatric patients (less than 3 months of age) 
Pediatrični bolniki (mlajši od 3 mesecev)
The studies presented in Table 2 were conducted in healthy subjects unless otherwise noted. 
Študije, navedene v preglednici 2, so bile izvedene pri zdravih osebah, če ni drugače navedeno.
The same recommendations for drug drug interactions would apply except: 
Upoštevati je treba enaka priporočila za medsebojno delovanje med zdravili, razen:
Food effect 
Učinek hrane
Table 5: Efficacy Outcomes in Study 138 
Preglednica 5: Izidi učinkovitosti v Študiji 138
(responder/evaluable) 
(bolniki z odzivom/ovrednoteno)
Didanosine (with food) 
didanozin (skupaj s hrano)
In the prepartum period, additional monitoring should be considered. 
V predporodnem obdobju je potrebno dodatno nadziranje.
An alternate reliable method of contraception is recommended. 
Priporočljiva je uporaba druge zanesljive metode kontracepcije.
Week 48 
48. teden
Difference estimate e 
Ocenjena razlika e
It is important to note that at time of the 96-week analysis, 48 % of patients overall remained on study. 
Omeniti je treba, da je bilo v študiji v času analize po 96 tednih v celoti še 48% bolnikov.
If it is almost time for your next dose, do not take the missed dose. 
Če je že skoraj čas za naslednji odmerek, ne vzemite pozabljenega odmerka.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve za predložitev redno posodobljenih poročil o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES in vseh nadaljnjih posodobitev, objavljenih na evropskem spletnem portalu o zdravilih.
A causal relationship has been suggested, although the mechanism of action has not been elucidated. 
Domnevamo, da gre za vzročno povezavo, vendar pa mehanizem delovanja ni pojasnjen.
Number of patients evaluable. 
Število ovrednotenih bolnikov.
Without tenofovir 
Brez tenofovirja
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
Consistent results were obtained with the last observation carried forward method of analysis (time-averaged difference of 0.11, 97.5% confidence interval [-0.15, 0.36]). 
Konsistentni rezultati so bili doseženi z analizo po metodi prenosa zadnjega opažanja naprej (časovno povprečna razlika 0,11 pri 97,5 % intervalu zaupanja [-0,15, 0,36]).
• undetectable viral load during the last 6 months under current regimen 
• nedokazljivo virusno breme v zadnjih 6 mesecih pri trenutnem režimu zdravljenja,
Week 96 
96. teden
Caution should be exercised. 
Potrebna je previdnost.
Your doctor will test for these changes. 
Zdravnik bo opravil presikave za omenjene spremembe.
Do not take a double dose to make up for a forgotten dose. 
Ne vzemite dvojnega odmerka, da bi nadomestili pozabljeni odmerek.
Tell your doctor if you notice anything unusual about your health. 
Povejte zdravniku, če ste opazili kar koli neobičajnega.
Single doses up to 1,200 mg have been taken by healthy volunteers without symptomatic untoward effects. 
Pri zdravih prostovoljcih posamični odmerki do 1.200 mg niso povzročili simptomatskih neželenih učinkov.
No differences in frequency of bilirubin elevations were observed between these patients and those without viral hepatitis. 
Razlik v pogostnosti zvišanja bilirubina med temi bolniki in tistimi brez virusnega hepatitisa niso opažali.
100 mg at least 35 
100 mg najmanj 35
Analyses of data through 96 weeks of treatment demonstrated durability of antiviral activity (Table 5). 
Analize podatkov po 96 tednih zdravljenja kažejo trajnost protivirusne aktivnosti (preglednica 5).
• if you are allergic to atazanavir or any of the other ingredients of this medicine (listed in section 6) 
• če ste alergični na atazanavir ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Do not use this medicine after the expiry date which is stated on the label, carton or blister. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki, škatli ali pretisnem omotu.
• hypersensitivity (allergic reaction) 
• preobčutljivost (alergijska reakcija);
Withdrawal of ritonavir only under restrictive conditions 
Odtegnitev ritonavirja le v omejenih pogojih
Thirty-two percent of patients in the study had a viral strain with fewer than two NRTI substitutions. 
Dvaintrideset odstotkov bolnikov v študiji je imelo virusni sev z manj kot dvema substitucijama za NRTI.
Such changes may in part be linked to the disease control and life style. 
Povišane je lahko deloma povezano z nadzorovanjem bolezni in življenjskim slogom.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• Ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja).
In more than half of the reported cases, treatment with protease inhibitors was continued or reintroduced if treatment had been discontinued. 
Pri več kot polovici primerov so zdravljenje z zaviralci proteaz nadaljevali ali ga znova uvedli, če je bilo prekinjeno.
Dosage adjustment for midazolam should be considered, especially if more than a single dose of midazolam is administered. 
Razmisliti je treba o prilagoditvi odmerka midazolama, še posebej, če se uporabi več kot le en odmerek midazolama.
Severe rash may be developed in association with other symptoms which could be serious. 
Hud kožni izpuščaj se lahko pojavi v povezavi z drugimi simptomi, ki so lahko resni.
Cmin is concentration 24 hours post-dose. 
Cmin je koncentracija 24 ur po uporabi odmerka.
Mylan S.A.S., 117 Allee des Parcs, Saint-Priest, 69800, France 
Mylan S.A.S., 117 Allee des Parcs, Saint-Priest, 69800, Francija
Consistent results were obtained with the last observation carried forward method of analysis. 
Konsistentne rezultate je dala analiza z uporabo metode prenosa zadnjega opažanja.
If you miss a dose, take the missed dose as soon as possible with food and then take your next scheduled dose at its regular time. 
Če ste pozabili vzeti odmerek, pozabljeni odmerek vzemite čimprej skupaj s hrano in nato vzemite naslednji predvideni odmerek ob običajnem času.
Some patients required hospitalization for additional management and some had complications. 
Pri nekaterih bolnikih je bilo potrebno dodatno zdravljenje v bolnišnici, pri nekaterih pa so se pojavili zapleti.
It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. 
Menijo, da so ti simptomi posledica izboljšanja telesnega imunskega odgovora, ki omogoča telesu, da se brani pred okužbami, ki so bile prej prisotne brez očitnih simptomov.
Frequency is defined using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000). 
Pogostost neželenih učinkov je opredeljena v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000).
This side effect is usually not dangerous in adults and infants older than 3 months of age; but it might be a symptom of a serious problem. 
Ta neželeni učinek pri odraslih in dojenčkih, starejših od 3 mesecev, običajno ni nevaren, vendar pa je lahko simptom resne težave.
Responders on LPV/RTV who completed treatment before Week 96 are excluded from Week 96 analysis. 
Bolniki, ki so se odzvali na zdravljenje z LPV/RTV in so dokončali zdravljenje pred 96. tednom v analizo 96- tedenskega zdravljenja niso vključeni.
Antiviral activity in vitro 
Protivirusno delovanje in vitro
Do not open the capsules. 
Kapsul ne odpirajte.
More frequent therapeutic concentration monitoring of these medicinal products is recommended until plasma levels have been stabilised. 
Priporočamo pogostejše spremljanje terapevtskih koncentracij teh zdravil, dokler se plazemske vrednosti ne ustalijo.
Per protocol analysis: Excluding non-completers and patients with major protocol deviations. 
Analiza po protokolu: Izključeni so bolniki, ki študije niso dokončali, in bolniki s pomembnimi odstopanji od protokola.
Per protocol analysis e 
Analiza po protokolu e
Clinical results 
Klinični rezultati
Electrocardiographic changes (sinus bradycardia, prolongation of PR interval, prolongation of QT interval, and prolongation of QRS complex) were observed only in an initial 2 week oral toxicity study performed in dogs. 
Elektrokardiografske spremembe (sinusna bradikardija, podaljšanje intervala PR, intervala QT in razširitev kompleksa QRS) so opazili samo v prvih 2 tednih študije peroralne toksičnosti pri psih.
• angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) 
• angioedem (hudo otekanje kože in drugih tkiv, najpogosteje ustnic ali oči);
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvezujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
Atazanavir Mylan capsules may be used by adults and children 6 years of age and older. 
Kapsule Atazanavir Mylan lahko uporabljajo odrasli in otroci, stari 6 let in več.
Administration of activated charcoal may also be used to aid removal of unabsorbed drug. 
Kot pomoč za odstranitev neabsorbiranega zdravila je mogoče uporabiti tudi aktivno oglje.
In the majority of cases, jaundice was reported within a few days to a few months after the initiation of treatment (see section 4.4). 
V večini primerov se je zlatenica pojavila v nekaj dneh do nekaj mesecih po uvedbi zdravljenja (glejte poglavje 4.4).
% (responder/evaluable d) 
% (bolniki z odzivom/ovrednoteno d)
Week 48: 1.7% [-3.8%, 7.1%] Week 96: 6.1% [0.3%, 12.0%] 
48. teden: 1,7 % [-3,8 %; 7,1 %] 96. teden: 6,1 % [0,3 %; 12,0 %]
The best results in managing these events come from early diagnosis and immediate interruption of any suspect medicines. 
Najboljše rezultate ukrepanja v primeru pojava teh neželenih učinkov je mogoče doseči z njihovim zgodnjim odkritjem in s takojšnjo prekinitvijo uporabe katerega koli sumljivega zdravila.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding. 
Bolnike s hemofilijo je zato treba opozoriti na možnost pogostejših krvavitev.
For dosing recommendations see section 4.2 and for pharmacokinetic data see section 5.2. 
Za priporočila o odmerjanju glejte poglavje 4.2 in za farmakokinetične podatke poglavje 5.2.
There were no cases of lactic acidosis observed in the clinical trial AI424-182. 
O pojavu laktacidoze v kliničnem preskušanju AI424-182 niso poročali.
Table 2: Interactions between atazanavir and other medicinal products 
Preglednica 2: Interakcije med atazanavirjem in drugimi zdravili
The fluticasone propionate plasma levels increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% confidence interval 82%- 89%). 
Plazemske vrednosti flutikazonpropionata so se znatno povečale, intrinzične vrednosti kortizola pa zmanjšale za približno 86 % (90 % interval zaupanja; 82-89 %).
Potential cardiac effects of this product in humans cannot be ruled out (see sections 4.4 and 4.8). 
Potencialnih učinkov tega zdravila na srce pri ljudeh ni mogoče izključiti (glejte poglavji 4.4 in 4.8).
There were no clinically important pharmacokinetic differences based on age or gender. 
Klinično pomembnih razlik v farmakokinetiki glede na spol ali starost niso ugotovili.
They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system. 
Zmanjša število virusov HIV v telesu in tako okrepi imunski sistem.
QT prolongation 
Podaljšanje intervala QT
In some cases, nephrolithiasis has been associated with acute renal failure or renal insufficiency. 
V nekaterih primerih je bila nefrolitiaza povezana z akutno odpovedjo ali insuficienco ledvic.
Dose reduction of atazanavir is not recommended because it may result in a loss of therapeutic effect and development of resistance. 
Zmanjšanje odmerka atazanavirja ni priporočljivo, ker lahko povzroči izgubo terapevtskega učinka in razvoj odpornosti.
Caution should be used with medicinal products known to induce PR prolongations. 
Previdnost je potrebna pri zdravilih, za katera je znano, da inducirajo podaljšanje intervala PR.
• if you have hepatitis B or C 
• če imate hepatitis B ali C,
There is a risk of loss of therapeutic effect and development of resistance (see section 4.3). 
Obstaja tveganje za izgubo terapevtskega učinka in razvoj odpornosti (glejte poglavje 4.3).
You may continue to develop infections or other illnesses linked to HIV infection. 
Kljub zdravljenju se lahko razvijejo okužbe ali druge bolezni, povezane z okužbo s HIV.
15 to less than 35 At least 35 * Ritonavir capsules, tablets or oral solution may be used. 
15 do manj kot 35 Najmanj 35 *Uporablja se lahko ritonavir v obliki kapsul, tablet ali peroralne raztopine.
• certain antibiotics (rifabutin, clarithromycin) 
• nekateri antibiotiki (rifabutin, klaritromicin),
Includes patients with baseline resistance data. 
Vključuje bolnike z izhodiščnimi podatki o odpornosti.
If you have liver problems, including hepatitis B or C infection, you may experience a worsening of your liver problems. 
Če imate težave z jetri, vključno z hepatitisom B ali C, se težave z jetri lahko poslabšajo.
The clinical data derived from this study are inadequate to support the use of atazanavir (with or without ritonavir) in children below 6 years of age. 
Klinični podatki iz te študije niso zadostni, da bi podprli uporabo atazanavirja (z ali brez ritonavirja) pri otrocih, mlajših od 6 let.
Store below 25°C. 
Shranjujte pri temperaturi do 25 °C.
This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. 
To je deloma povezano s povrnjenim zdravjem in življenskim slogom in v primeru lipidov v krvi včasih z zdravili za zdravljenje HIVa.
Difference estimate [95% CI] 
Ocenjena razlika [95 % interval zaupanja]
NA = not applicable. 
NA = Navedba smiselno ni potrebna.
Moreover, in case of withdrawal of glucocorticoids, progressive dose reduction may have to be performed over a longer period. 
V primeru prekinitve zdravljenja z glukokortikoidom bo morda treba odmerek zmanjševati postopoma daljši čas.
Similar concentrations of atazanavir increased by 13% the action potential duration (APD90) in rabbit Purkinje fibres study. 
Podobne koncentracije atazanavirja so za 13 % podaljšale trajanje akcijskega potenciala (APD90) v študiji s kunčjimi Purkinjevimi vlakni.
Immune reactivation syndrome 
Sindrom imunske reaktivacije